Pharmacological treatment in Parkinson's disease: Effects on gait

Parkinsonism and Related Disorders

Volumn 31, Issue , 2016, Pages 3-13

  Smulders, Katrijn ^a   Dale, Marian L ^a   Carlson Kuhta, Patricia ^a   Nutt, John G ^a   Horak, Fay B ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Acetylcholine; Dopamine; Falls; Gait; Turning

Indexed keywords

ACETYLCHOLINE; AMANTADINE; ANTIDEPRESSANT AGENT; APOMORPHINE; BENZODIAZEPINE DERIVATIVE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINESTERASE INHIBITOR; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; DROXIDOPA; ENTACAPONE; HYPNOTIC AGENT; HYPNOTIC SEDATIVE AGENT; LEVODOPA; MEMANTINE; METHYLPHENIDATE; MONOAMINE OXIDASE B INHIBITOR; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; PERGOLIDE; PLACEBO; PRAMIPEXOLE; RASAGILINE; RIVASTIGMINE; SELEGILINE; TOLCAPONE; ANTIPARKINSON AGENT;

BRADYKINESIA; COMORBIDITY; DISABILITY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; FALLING; GAIT; GAIT DISORDER; HUMAN; MONOTHERAPY; MUSCLE RIGIDITY; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; TREMOR; WALKING; BODY EQUILIBRIUM; COMPLICATION; DRUG EFFECTS; METABOLISM; NEUROLOGIC GAIT DISORDER; PREVENTION AND CONTROL;

ACCIDENTAL FALLS; ACETYLCHOLINE; ANTIPARKINSON AGENTS; DOPAMINE AGENTS; GAIT DISORDERS, NEUROLOGIC; HUMANS; PARKINSON DISEASE; POSTURAL BALANCE;

EID: 84994320305     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2016.07.006     Document Type: Review

References (136)

1. [1] Rochester, L., Galna, B., Lord, S., Burn, D., The nature of dual-task interference during gait in incident Parkinson's disease. Neuroscience 265 (2014), 83–94.
2. [2] Baltadjieva, R., Giladi, N., Gruendlinger, L., Peretz, C., Hausdorff, J.M., Marked alterations in the gait timing and rhythmicity of patients with de novo Parkinson's disease. Eur. J. Neurosci. 24:6 (2006), 1815–1820.
3. [3] Yang, Y.R., Lee, Y.Y., Cheng, S.J., Lin, P.Y., Wang, R.Y., Relationships between gait and dynamic balance in early Parkinson's disease. Gait Posture 27:4 (2008), 611–615.
4. [4] Zampieri, C., Salarian, A., Carlson-Kuhta, P., Aminian, K., Nutt, J.G., Horak, F.B., The instrumented timed up and go test: potential outcome measure for disease modifying therapies in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 81:2 (2010), 171–176.
5. [5] Grimbergen, Y.A., Munneke, M., Bloem, B.R., Falls in Parkinson's disease. Curr. Opin. Neurol. 17:4 (2004), 405–415.
6. [6] Galna, B., Lord, S., Burn, D.J., Rochester, L., Progression of gait dysfunction in incident Parkinson's disease: impact of medication and phenotype. Mov. Disord. 30:3 (2015), 359–367.
7. [7] Vervoort, G., Bengevoord, A., Strouwen, C., Bekkers, E.M., Heremans, E., Vandenberghe, W., Nieuwboer, A., Progression of postural control and gait deficits in Parkinson's disease and freezing of gait: a longitudinal study. Park. Relat. Disord. 28 (2016), 73–79.
8. [8] Walton, C.C., Shine, J.M., Hall, J.M., O'Callaghan, C., Mowszowski, L., Gilat, M., Szeto, J.Y., Naismith, S.L., Lewis, S.J., The major impact of freezing of gait on quality of life in Parkinson's disease. J. Neurol. 262:1 (2015), 108–115.
9. [9] Muslimovic, D., Post, B., Speelman, J.D., Schmand, B., De Haan, R.J., Determinants of disability and quality of life in mild to moderate Parkinson disease. Neurology 70:23 (2008), 2241–2247.
10. [10] Dubost, V., Kressig, R.W., Gonthier, R., Herrmann, F.R., Aminian, K., Najafi, B., Beauchet, O., Relationships between dual-task related changes in stride velocity and stride time variability in healthy older adults. Hum. Mov. Sci. 25:3 (2006), 372–382.
11. [11] Patel, P., Lamar, M., Bhatt, T., Effect of type of cognitive task and walking speed on cognitive-motor interference during dual-task walking. Neuroscience 260 (2014), 140–148.
12. [12] Dibilio, V., Stummer, C., Drenthen, L., Bloem, B.R., Nonnekes, J., Weerdesteyn, V., Secondary task performance during challenging walking tasks and freezing episodes in Parkinson's disease. J. Neural Transm. 123:5 (2016), 495–501.
13. [13] Mancini, M., El-Gohary, M., Pearson, S., McNames, J., Schlueter, H., Nutt, J.G., King, L.A., Horak, F.B., Continuous monitoring of turning in Parkinson's disease: rehabilitation potential. NeuroRehabilitation 37:1 (2015), 3–10.
14. [14] Patla, A.E., Adkin, A., Ballard, T., Online steering: coordination and control of body center of mass, head and body reorientation. Exp. Brain Res. 129:4 (1999), 629–634.
15. [15] Mellone, S., Mancini, M., King, L.A., Horak, F.B., Chiari, L., The quality of turning in Parkinson's disease: a compensatory strategy to prevent postural instability?. J. Neuroeng. Rehabil., 13, 2016, 39.
16. [16] Smulders, K., van Swigchem, R., de Swart, B.J., Geurts, A.C., Weerdesteyn, V., Community-dwelling people with chronic stroke need disproportionate attention while walking and negotiating obstacles. Gait Posture 36:1 (2012), 127–132.
17. [17] Weerdesteyn, V., Schillings, A.M., van Galen, G.P., Duysens, J., Distraction affects the performance of obstacle avoidance during walking. J. Mot. Behav. 35:1 (2003), 53–63.
18. [18] Hegeman, J., Weerdesteyn, V., van den Bemt, B., Nienhuis, B., van Limbeek, J., Duysens, J., Dual-tasking interferes with obstacle avoidance reactions in healthy seniors. Gait Posture 36:2 (2012), 236–240.
19. [19] Morris, M.E., Iansek, R., Matyas, T.A., Summers, J.J., The pathogenesis of gait hypokinesia in Parkinson's disease. Brain 117:Pt 5 (1994), 1169–1181.
20. [20] Morris, M.E., Iansek, R., Matyas, T.A., Summers, J.J., Ability to modulate walking cadence remains intact in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 57:12 (1994), 1532–1534.
21. [21] Burleigh-Jacobs, A., Horak, F.B., Nutt, J.G., Obeso, J.A., Step initiation in Parkinson's disease: influence of levodopa and external sensory triggers. Mov. Disord. 12:2 (1997), 206–215.
22. [22] Nieuwboer, A., De Weerdt, W., Dom, R., Peeraer, L., Lesaffre, E., Hilde, F., Baunach, B., Plantar force distribution in Parkinsonian gait: a comparison between patients and age-matched control subjects. Scand. J. Rehabil. Med. 31:3 (1999), 185–192.
23. [23] Bowes, S.G., Clark, P.K., Leeman, A.L., O'Neill, C.J., Weller, C., Nicholson, P.W., Deshmukh, A.A., Dobbs, S.M., Dobbs, R.J., Determinants of gait in the elderly parkinsonian on maintenance levodopa/carbidopa therapy. Br. J. Clin. Pharmacol. 30:1 (1990), 13–24.
24. [24] Sterling, N.W., Cusumano, J.P., Shaham, N., Piazza, S.J., Liu, G., Kong, L., Du, G., Lewis, M.M., Huang, X., Dopaminergic modulation of arm swing during gait among Parkinson's disease patients. J. Parkinson's Dis. 5:1 (2015), 141–150.
25. [25] Hausdorff, J.M., Gait variability: methods, modeling and meaning. J. Neuroeng. Rehabil., 2, 2005, 19.
26. [26] Plotnik, M.P., Giladi, M.N., Dagan, Y., Hausdorff, J.M., Postural instability and fall risk in Parkinson's disease: impaired dual tasking, pacing, and bilateral coordination of gait during the “ON” medication state. Exp. Brain Res. 210:3–4 (2011), 529–538.
27. [27] Weiss, A., Herman, T., Giladi, N., Hausdorff, J.M., Objective assessment of fall risk in Parkinson's disease using a body-fixed sensor worn for 3 days. PLoS One, 9(5), 2014, e96675.
28. [28] Smulders, K., Esselink, R.A., Weiss, A., Kessels, R.P., Geurts, A.C., Bloem, B.R., Assessment of dual tasking has no clinical value for fall prediction in Parkinson's disease. J. Neurol. 259:9 (2012), 1840–1847.
29. [29] Jacobs, J.V., Nutt, J.G., Carlson-Kuhta, P., Stephens, M., Horak, F.B., Knee trembling during freezing of gait represents multiple anticipatory postural adjustments. Exp. Neurol. 215:2 (2009), 334–341.
30. [30] Rosin, R., Topka, H., Dichgans, J., Gait initiation in Parkinson's disease. Mov. Disord. 12:5 (1997), 682–690.
31. [31] Roemmich, R.T., Nocera, J.R., Vallabhajosula, S., Amano, S., Naugle, K.M., Stegemoller, E.L., Hass, C.J., Spatiotemporal variability during gait initiation in Parkinson's disease. Gait Posture 36:3 (2012), 340–343.
32. [32] Vallabhajosula, S., Buckley, T.A., Tillman, M.D., Hass, C.J., Age and Parkinson's disease related kinematic alterations during multi-directional gait initiation. Gait Posture 37:2 (2013), 280–286.
33. [33] Rocchi, L., Chiari, L., Mancini, M., Carlson-Kuhta, P., Gross, A., Horak, F.B., Step initiation in Parkinson's disease: influence of initial stance conditions. Neurosci. Lett. 406:1–2 (2006), 128–132.
34. [34] Crenna, P., Carpinella, I., Rabuffetti, M., Calabrese, E., Mazzoleni, P., Nemni, R., Ferrarin, M., The association between impaired turning and normal straight walking in Parkinson's disease. Gait Posture 26:2 (2007), 172–178.
35. [35] Huxham, F., Baker, R., Morris, M.E., Iansek, R., Head and trunk rotation during walking turns in Parkinson's disease. Mov. Disord. Off. J. Mov. Disord. Soc. 23:10 (2008), 1391–1397.
36. [36] Visser, J.E., Voermans, N.C., Oude Nijhuis, L.B., van der Eijk, M., Nijk, R., Munneke, M., Bloem, B.R., Quantification of trunk rotations during turning and walking in Parkinson's disease. Clin. Neurophysiol. Off. J. Int. Fed. Clin. Neurophysiol. 118:7 (2007), 1602–1606.
37. [37] Ashburn, A., Kampshoff, C., Burnett, M., Stack, E., Pickering, R.M., Verheyden, G., Sequence and onset of whole-body coordination when turning in response to a visual trigger: comparing people with Parkinson's disease and healthy adults. Gait posture 39:1 (2014), 278–283.
38. [38] Franzen, E., Paquette, C., Gurfinkel, V.S., Cordo, P.J., Nutt, J.G., Horak, F.B., Reduced performance in balance, walking and turning tasks is associated with increased neck tone in Parkinson's disease. Exp. Neurol. 219:2 (2009), 430–438.
39. [39] Hong, M., Perlmutter, J.S., Earhart, G.M., A kinematic and electromyographic analysis of turning in people with Parkinson disease. Neurorehabil. Neural Repair 23:2 (2009), 166–176.
40. [40] Huxham, F., Baker, R., Morris, M.E., Iansek, R., Footstep adjustments used to turn during walking in Parkinson's disease. Mov. Disord. 23:6 (2008), 817–823.
41. [41] Stack, E., Ashburn, A., Dysfunctional turning in Parkinson's disease. Disabil. Rehabil. 30:16 (2008), 1222–1229.
42. [42] Vitorio, R., Lirani-Silva, E., Baptista, A.M., Barbieri, F.A., dos Santos, P.C., Teixeira-Arroyo, C., Gobbi, L.T., Disease severity affects obstacle crossing in people with Parkinson's disease. Gait Posture 40:1 (2014), 266–269.
43. [43] Vitorio, R., Lirani-Silva, E., Barbieri, F.A., Raile, V., Stella, F., Gobbi, L.T., Influence of visual feedback sampling on obstacle crossing behavior in people with Parkinson's disease. Gait Posture 38:2 (2013), 330–334.
44. [44] Galna, B., Murphy, A.T., Morris, M.E., Obstacle crossing in people with Parkinson's disease: foot clearance and spatiotemporal deficits. Hum. Mov. Sci. 29:5 (2010), 843–852.
45. [45] Doan, J.B., de Bruin, N., Pellis, S.M., Suchowersky, O., Whishaw, I.Q., Brown, L.A., Obstacle avoidance amongst Parkinson disease patients is challenged in a threatening context. J. Neurodegener. Dis., 2013, 2013, 787861.
46. [46] Galna, B., Murphy, A.T., Morris, M.E., Obstacle crossing in Parkinson's disease: mediolateral sway of the centre of mass during level-ground walking and obstacle crossing. Gait Posture 38:4 (2013), 790–794.
47. [47] Stegemoller, E.L., Buckley, T.A., Pitsikoulis, C., Barthelemy, E., Roemmich, R., Hass, C.J., Postural instability and gait impairment during obstacle crossing in Parkinson's disease. Arch. Phys. Med. Rehabil. 93:4 (2012), 703–709.
48. [48] Forsaa, E.B., Larsen, J.P., Wentzel-Larsen, T., Alves, G., A 12-year population-based study of freezing of gait in Parkinson's disease. Park. Relat. Disord. 21:3 (2015), 254–258.
49. [49] Knobl, P., Kielstra, L., Almeida, Q., The relationship between motor planning and freezing of gait in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 83:1 (2012), 98–101.
50. [50] Peterson, D.S., Fling, B.W., Mancini, M., Cohen, R.G., Nutt, J.G., Horak, F.B., Dual-task interference and brain structural connectivity in people with Parkinson's disease who freeze. J. Neurol. Neurosurg. Psychiatry 86:7 (2015), 786–792.
51. [51] Fietzek, U.M., Zwosta, J., Schroeteler, F.E., Ziegler, K., Ceballos-Baumann, A.O., Levodopa changes the severity of freezing in Parkinson's disease. Park. Relat. Disord. 19:10 (2013), 894–896.
52. [52] Plotnik, M., Giladi, N., Balash, Y., Peretz, C., Hausdorff, J.M., Is freezing of gait in Parkinson's disease related to asymmetric motor function?. Ann. Neurol. 57:5 (2005), 656–663.
53. [53] Bengevoord, A., Vervoort, G., Spildooren, J., Heremans, E., Vandenberghe, W., Bloem, B.R., Nieuwboer, A., Center of mass trajectories during turning in patients with Parkinson's disease with and without freezing of gait. Gait Posture 43 (2016), 54–59.
54. [54] Woollacott, M., Shumway-Cook, A., Attention and the control of posture and gait: a review of an emerging area of research. Gait Posture 16:1 (2002), 1–14.
55. [55] Yogev, G., Giladi, N., Peretz, C., Springer, S., Simon, E.S., Hausdorff, J.M., Dual tasking, gait rhythmicity, and Parkinson's disease: which aspects of gait are attention demanding?. Eur. J. Neurosci. 22:5 (2005), 1248–1256.
56. [56] Spildooren, J., Vercruysse, S., Desloovere, K., Vandenberghe, W., Kerckhofs, E., Nieuwboer, A., Freezing of gait in Parkinson's disease: the impact of dual-tasking and turning. Mov. Disord. 25:15 (2010), 2563–2570.
57. [57] Fregni, F., Boggio, P.S., Bermpohl, F., Maia, F., Rigonatti, S.P., Barbosa, E.R., Pascual-Leone, A., Immediate placebo effect in Parkinson's disease–is the subjective relief accompanied by objective improvement?. Eur. Neurol. 56:4 (2006), 222–229.
58. [58] Rochester, L., Baker, K., Nieuwboer, A., Burn, D., Targeting dopa-sensitive and dopa-resistant gait dysfunction in Parkinson's disease: selective responses to internal and external cues. Mov. Disord. 26:3 (2011), 430–435.
59. [59] Curtze, C., Nutt, J.G., Carlson-Kuhta, P., Mancini, M., Horak, F.B., Levodopa is a double-edged Sword for balance and gait in people with Parkinson's disease. Mov. Disord. 30:10 (2015), 1361–1370.
60. [60] Blin, O., Ferrandez, A.M., Pailhous, J., Serratrice, G., Dopa-sensitive and dopa-resistant gait parameters in Parkinson's disease. J. Neurol. Sci. 103:1 (1991), 51–54.
61. [61] Bryant, M.S., Rintala, D.H., Hou, J.G., Charness, A.L., Fernandez, A.L., Collins, R.L., Baker, J., Lai, E.C., Protas, E.J., Gait variability in Parkinson's disease: influence of walking speed and dopaminergic treatment. Neurol. Res. 33:9 (2011), 959–964.
62. [62] Bohnen, N.I., Cham, R., Postural control, gait, and dopamine functions in parkinsonian movement disorders. Clin. Geriatr. Med. 22:4 (2006), 797–812.
63. [63] Hong, M., Earhart, G.M., Effects of medication on turning deficits in individuals with Parkinson's disease, Journal of neurologic physical therapy. JNPT 34:1 (2010), 11–16.
64. [64] Pieruccini-Faria, F., Vitorio, R., Almeida, Q.J., Silveira, C.R., Caetano, M.J., Stella, F., Gobbi, S., Gobbi, L.T., Evaluating the acute contributions of dopaminergic replacement to gait with obstacles in Parkinson's disease. J. Mot. Behav. 45:5 (2013), 369–380.
65. [65] Barbe, M.T., Amarell, M., Snijders, A.H., Florin, E., Quatuor, E.L., Schonau, E., Fink, G.R., Bloem, B.R., Timmermann, L., Gait and upper limb variability in Parkinson's disease patients with and without freezing of gait. J. Neurol. 261:2 (2014), 330–342.
66. [66] Schaafsma, J.D., Giladi, N., Balash, Y., Bartels, A.L., Gurevich, T., Hausdorff, J.M., Gait dynamics in Parkinson's disease: relationship to Parkinsonian features, falls and response to levodopa. J. Neurol. Sci. 212:1–2 (2003), 47–53.
67. [67] Espay, A.J., Fasano, A., van Nuenen, B.F., Payne, M.M., Snijders, A.H., Bloem, B.R., “On” state freezing of gait in Parkinson disease: a paradoxical levodopa-induced complication. Neurology 78:7 (2012), 454–457.
68. [68] Fahn, S., Does levodopa slow or hasten the rate of progression of Parkinson's disease?. J. Neurol. 252:Suppl 4 (2005), IV37–IV42.
69. [69] Chang, F.C., Tsui, D.S., Mahant, N., Wolfe, N., Kim, S.D., Ha, A.D., Drury, M., Griffith, J.M., Fung, V.S., 24 h Levodopa-carbidopa intestinal gel may reduce falls and “unresponsive” freezing of gait in Parkinson's disease. Park. Relat. Disord. 21:3 (2015), 317–320.
70. [70] Fox, S.H., Katzenschlager, R., Lim, S.Y., Ravina, B., Seppi, K., Coelho, M., Poewe, W., Rascol, O., Goetz, C.G., Sampaio, C., The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov. Disord. 26:Suppl 3 (2011), S2–S41.
71. [71] Serrao, M., Ranavolo, A., Conte, C., Davassi, C., Mari, S., Fasano, A., Chini, G., Coppola, G., Draicchio, F., Pierelli, F., Effect of 24-h continuous rotigotine treatment on stationary and non-stationary locomotion in de novo patients with Parkinson disease in an open-label uncontrolled study. J. Neurol. 262:11 (2015), 2539–2547.
72. [72] Ondo, W., Hunter, C., Almaguer, M., Gancher, S., Jankovic, J., Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease. Clin. Neuropharmacol. 22:1 (1999), 1–4.
73. [73] Brodsky, M.A., Park, B.S., Nutt, J.G., Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease. Arch. Neurol. 67:1 (2010), 27–32.
74. [74] Olanow, C.W., Fahn, S., Muenter, M., Klawans, H., Hurtig, H., Stern, M., Shoulson, I., Kurlan, R., Grimes, J.D., Jankovic, J., et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov. Disord. 9:1 (1994), 40–47.
75. [75] Napolitano, A., Del Dotto, P., Petrozzi, L., Dell'Agnello, G., Bellini, G., Gambaccini, G., Bonuccelli, U., Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease. Clin. Neuropharmacol. 22:1 (1999), 24–29.
76. [76] Ondo, W.G., Hunter, C., Vuong, K.D., Jankovic, J., The pharmacokinetic and clinical effects of tolcapone on a single dose of sublingual apomorphine in Parkinson's disease. Park. Relat. Disord. 6:4 (2000), 237–240.
77. [77] Group, P.S., DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Arch. Neurol. 46:10 (1989), 1052–1060.
78. [78] Olanow, C.W., Rascol, O., Hauser, R., Feigin, P.D., Jankovic, J., Lang, A., Langston, W., Melamed, E., Poewe, W., Stocchi, F., Tolosa, E., Investigators, A.S., A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 361:13 (2009), 1268–1278.
79. [79] Shoulson, I., DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism. Ann. Neurol. 44:3 Suppl 1 (1998), S160–S166.
80. [80] Giladi, N., McDermott, M.P., Fahn, S., Przedborski, S., Jankovic, J., Stern, M., Tanner, C., Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 56:12 (2001), 1712–1721.
81. [81] Jankovic, J., Berkovich, E., Eyal, E., Tolosa, E., Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: post-hoc analyses from the ADAGIO trial. Park. Relat. Disord. 20:6 (2014), 640–643.
82. [82] Hubble, J.P., Koller, W.C., Waters, C., Effects of selegiline dosing on motor fluctuations in Parkinson's disease. Clin. Neuropharmacol. 16:1 (1993), 83–87.
83. [83] Dashtipour, K., Chen, J.J., Kani, C., Bahjri, K., Ghamsary, M., Clinical outcomes in patients with Parkinson's disease treated with a monoamine oxidase Type-B inhibitor: a cross-sectional, cohort study. Pharmacotherapy 35:7 (2015), 681–686.
84. [84] Malkani, R., Zadikoff, C., Melen, O., Videnovic, A., Borushko, E., Simuni, T., Amantadine for freezing of gait in patients with Parkinson disease. Clin. Neuropharmacol. 35:6 (2012), 266–268.
85. [85] Lee, J.Y., Oh, S., Kim, J.M., Kim, J.S., Oh, E., Kim, H.T., Jeon, B.S., Cho, J.W., Intravenous amantadine on freezing of gait in Parkinson's disease: a randomized controlled trial. J. Neurol. 260:12 (2013), 3030–3038.
86. [86] Kim, Y.E., Yun, J.Y., Yang, H.J., Kim, H.J., Gu, N., Yoon, S.H., Cho, J.Y., Jeon, B.S., Intravenous amantadine for freezing of gait resistant to dopaminergic therapy: a randomized, double-blind, placebo-controlled, cross-over clinical trial. PLoS One, 7(11), 2012, e48890.
87. [87] Chan, H.F., Kukkle, P.L., Merello, M., Lim, S.Y., Poon, Y.Y., Moro, E., Amantadine improves gait in PD patients with STN stimulation. Park. Relat. Disord. 19:3 (2013), 316–319.
88. [88] Beauchet, O., Launay, C.P., Allali, G., Watfa, G., Gallouj, K., Herrmann, F.R., Annweiler, C., Anti-dementia drugs and changes in gait: a pre-post quasi-experimental pilot study. BMC Neurol., 13, 2013, 184.
89. [89] Moreau, C., Delval, A., Tiffreau, V., Defebvre, L., Dujardin, K., Duhamel, A., Petyt, G., Hossein-Foucher, C., Blum, D., Sablonniere, B., Schraen, S., Allorge, D., Destee, A., Bordet, R., Devos, D., Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study. J. Neurol. Neurosurg. Psychiatry 84:5 (2013), 552–555.
90. [90] Bohnen, N.I., Frey, K.A., Studenski, S., Kotagal, V., Koeppe, R.A., Scott, P.J., Albin, R.L., Muller, M.L., Gait speed in Parkinson disease correlates with cholinergic degeneration. Neurology 81:18 (2013), 1611–1616.
91. [91] Bohnen, N.I., Muller, M.L., Koeppe, R.A., Studenski, S.A., Kilbourn, M.A., Frey, K.A., Albin, R.L., History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 73:20 (2009), 1670–1676.
92. [92] Muller, M.L., Bohnen, N.I., Cholinergic dysfunction in Parkinson's disease. Curr. Neurol. Neurosci. Rep., 13(9), 2013, 377.
93. [93] Rochester, L., Yarnall, A.J., Baker, M.R., David, R.V., Lord, S., Galna, B., Burn, D.J., Cholinergic dysfunction contributes to gait disturbance in early Parkinson's disease. Brain 135:Pt 9 (2012), 2779–2788.
94. [94] Karachi, C., Grabli, D., Bernard, F.A., Tande, D., Wattiez, N., Belaid, H., Bardinet, E., Prigent, A., Nothacker, H.P., Hunot, S., Hartmann, A., Lehericy, S., Hirsch, E.C., Francois, C., Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. J. Clin. Invest. 120:8 (2010), 2745–2754.
95. [95] Kelly, V.E., Shumway-Cook, A., The ability of people with Parkinson's disease to modify dual-task performance in response to instructions during simple and complex walking tasks. Exp. Brain Res. 232:1 (2014), 263–271.
96. [96] Stegemoller, E.L., Wilson, J.P., Hazamy, A., Shelley, M.C., Okun, M.S., Altmann, L.J., Hass, C.J., Associations between cognitive and gait performance during single- and dual-task walking in people with Parkinson disease. Phys. Ther. 94:6 (2014), 757–766.
97. [97] Emre, M., Aarsland, D., Albanese, A., Byrne, E.J., Deuschl, G., De Deyn, P.P., Durif, F., Kulisevsky, J., van Laar, T., Lees, A., Poewe, W., Robillard, A., Rosa, M.M., Wolters, E., Quarg, P., Tekin, S., Lane, R., Rivastigmine for dementia associated with Parkinson's disease. N. Engl. J. Med. 351:24 (2004), 2509–2518.
98. [98] Chung, K.A., Lobb, B.M., Nutt, J.G., Horak, F.B., Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 75:14 (2010), 1263–1269.
99. [99] Assal, F., Allali, G., Kressig, R.W., Herrmann, F.R., Beauchet, O., Galantamine improves gait performance in patients with Alzheimer's disease. J. Am. Geriatr. Soc. 56:5 (2008), 946–947.
100. [100] Beauchet, O., Launay, C.P., Montero-Odasso, M., Annweiler, C., Allali, G., Anti-dementia drugs-related changes in gait performance while single and dual tasking in patients with Alzheimer disease: a meta-analysis. Curr. Alzheimer Res. 12:8 (2015), 761–771.
101. [101] Montero-Odasso, M., Muir-Hunter, S.W., Oteng-Amoako, A., Gopaul, K., Islam, A., Borrie, M., Wells, J., Speechley, M., Donepezil improves gait performance in older adults with mild Alzheimer's disease: a phase II clinical trial. J. Alzheimers Dis. 43:1 (2015), 193–199.
102. [102] Henderson, E.J., Lord, S.R., Brodie, M.A., Gaunt, D.M., Lawrence, A.D., Close, J.C., Whone, A.L., Ben-Shlomo, Y., Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 15:3 (2016), 249–258.
103. [103] Henderson, E.J., Lord, S.R., Close, J.C., Lawrence, A.D., Whone, A., Ben-Shlomo, Y., The ReSPonD trial–rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen. BMC Neurol., 13, 2013, 188.
104. [104] Narabayashi, H., Kondo, T., Hayashi, A., Suzuki, T., Nagatsu, T., L-threo-3,4-dihydroxyphenylserine treatment for akinesia and freezing of parkinsonism. Proc. Jpn. Acad. 57:B (1982), 351–354.
105. [105] Tohgi, H., Abe, T., Takahashi, S., The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients. J. Neural Transm. Park. Dis. Dement. Sect. 5:1 (1993), 27–34.
106. [106] Fukada, K., Endo, T., Yokoe, M., Hamasaki, T., Hazama, T., Sakoda, S., L-threo-3,4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson's disease. Med. Hypotheses 80:2 (2013), 209–212.
107. [107] Kaufmann, H., Norcliffe-Kaufmann, L., Palma, J.A., Droxidopa in neurogenic orthostatic hypotension. Expert Rev. Cardiovasc. Ther. 13:8 (2015), 875–891.
108. [108] Hauser, R.A., Isaacson, S., Lisk, J.P., Hewitt, L.A., Rowse, G., Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B). Mov. Disord. 30:5 (2015), 646–654.
109. [109] Storebo, O.J., Ramstad, E., Krogh, H.B., Nilausen, T.D., Skoog, M., Holmskov, M., Rosendal, S., Groth, C., Magnusson, F.L., Moreira-Maia, C.R., Gillies, D., Buch Rasmussen, K., Gauci, D., Zwi, M., Kirubakaran, R., Forsbol, B., Simonsen, E., Gluud, C., Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst. Rev., 11, 2015, CD009885.
110. [110] Auriel, E., Hausdorff, J.M., Herman, T., Simon, E.S., Giladi, N., Effects of methylphenidate on cognitive function and gait in patients with Parkinson's disease: a pilot study. Clin. Neuropharmacol. 29:1 (2006), 15–17.
111. [111] Nutt, J.G., Carter, J.H., Carlson, N.E., Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial. Arch. Neurol. 64:3 (2007), 319–323.
112. [112] Devos, D., Krystkowiak, P., Clement, F., Dujardin, K., Cottencin, O., Waucquier, N., Ajebbar, K., Thielemans, B., Kroumova, M., Duhamel, A., Destee, A., Bordet, R., Defebvre, L., Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 78:5 (2007), 470–475.
113. [113] Delval, A., Moreau, C., Bleuse, S., Guehl, D., Bestaven, E., Guillaud, E., Dujardin, K., Defebvre, L., Devos, D., Gait and attentional performance in freezers under methylphenidate. Gait Posture 41:2 (2015), 384–388.
114. [114] Espay, A.J., Dwivedi, A.K., Payne, M., Gaines, L., Vaughan, J.E., Maddux, B.N., Slevin, J.T., Gartner, M., Sahay, A., Revilla, F.J., Duker, A.P., Shukla, R., Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial. Neurology 76:14 (2011), 1256–1262.
115. [115] Woolcott, J.C., Richardson, K.J., Wiens, M.O., Patel, B., Marin, J., Khan, K.M., Marra, C.A., Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch. Intern. Med. 169:21 (2009), 1952–1960.
116. [116] Thapa, P.B., Gideon, P., Cost, T.W., Milam, A.B., Ray, W.A., Antidepressants and the risk of falls among nursing home residents. N. Engl. J. Med. 339:13 (1998), 875–882.
117. [117] Leipzig, R.M., Cumming, R.G., Tinetti, M.E., Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J. Am. Geriatr. Soc. 47:1 (1999), 30–39.
118. [118] Costa-Dias, M.J., Oliveira, A.S., Martins, T., Araujo, F., Santos, A.S., Moreira, C.N., Jose, H., Medication fall risk in old hospitalized patients: a retrospective study. Nurse Educ. Today 34:2 (2014), 171–176.
119. [119] O'Neil, C.A., Krauss, M.J., Bettale, J., Kessels, A., Costantinou, E., Dunagan, W.C., Fraser, V.J., Medications and patient characteristics associated with falling in the hospital. J. Patient Saf., 2015 (Epub ahead of print).
120. [120] Krauss, M.J., Evanoff, B., Hitcho, E., Ngugi, K.E., Dunagan, W.C., Fischer, I., Birge, S., Johnson, S., Costantinou, E., Fraser, V.J., A case-control study of patient, medication, and care-related risk factors for inpatient falls. J. Gen. Intern. Med. 20:2 (2005), 116–122.
121. [121] Leipzig, R.M., Cumming, R.G., Tinetti, M.E., Drugs and falls in older people: a systematic review and meta-analysis: II. Cardiac and analgesic drugs. J. Am. Geriatr. Soc. 47:1 (1999), 40–50.
122. [122] Taipale, H.T., Bell, J.S., Gnjidic, D., Sulkava, R., Hartikainen, S., Sedative load among community-dwelling people aged 75 years or older: association with balance and mobility. J. Clin. Psychopharmacol. 32:2 (2012), 218–224.
123. [123] Hegeman, J., van den Bemt, B., Weerdesteyn, V., Nienhuis, B., van Limbeek, J., Duysens, J., Unraveling the association between SSRI use and falls: an experimental study of risk factors for accidental falls in long-term paroxetine users. Clin. Neuropharmacol. 34:6 (2011), 210–215.
124. [124] Draganich, L.F., Zacny, J., Klafta, J., Karrison, T., The effects of antidepressants on obstructed and unobstructed gait in healthy elderly people. J. Gerontol. A Biol. Sci. Med. Sci. 56:1 (2001), M36–M41.
125. [125] Hohler, A.D., Amariei, D.E., Katz, D.I., DePiero, T.J., Allen, V.B., Boyle, S., Phenix, H.A., DeAngelis, T.A., Geibel, C.D., Smith, K.M., Saint-Hilaire, M., Ellis, T., Treating orthostatic hypotension in patients with Parkinson's disease and atypical Parkinsonism improves function. J. Parkinson's Dis. 2:3 (2012), 235–240.
126. [126] Nebes, R.D., Pollock, B.G., Halligan, E.M., Kirshner, M.A., Houck, P.R., Serum anticholinergic activity and motor performance in elderly persons. J. Gerontol. A Biol. Sci. Med. Sci. 62:1 (2007), 83–85.
127. [127] Aizenberg, D., Sigler, M., Weizman, A., Barak, Y., Anticholinergic burden and the risk of falls among elderly psychiatric inpatients: a 4-year case-control study. Int. Psychogeriatr. 14:3 (2002), 307–310.
128. [128] Hegeman, J., Weerdesteyn, V., van den Bemt, B.J., Nienhuis, B., van Limbeek, J., Duysens, J., Even low alcohol concentrations affect obstacle avoidance reactions in healthy senior individuals. BMC Res. Notes, 3, 2010, 243.
129. [129] Kool, B., Ameratunga, S., Robinson, E., Crengle, S., Jackson, R., The contribution of alcohol to falls at home among working-aged adults. Alcohol 42:5 (2008), 383–388.
130. [130] Kerr, G.K., Worringham, C.J., Cole, M.H., Lacherez, P.F., Wood, J.M., Silburn, P.A., Predictors of future falls in Parkinson disease. Neurology 75:2 (2010), 116–124.
131. [131] Latt, M.D., Lord, S.R., Morris, J.G.L., Fung, V.S.C., Clinical and physiological assessments for elucidating falls risk in Parkinson's disease. Mov. Disord. 24:9 (2009), 1280–1289.
132. [132] Lord, S., Galna, B., Verghese, J., Coleman, S., Burn, D., Rochester, L., Independent domains of gait in older adults and associated motor and nonmotor attributes: validation of a factor analysis approach. J. Gerontol. A Biol. Sci. Med. Sci. 68:7 (2013), 820–827.
133. [133] Horak, F.B., Mancini, M., Carlson-Kuhta, P., Nutt, J.G., Salarian, A., Balance, Represent, Gait, Independent domains of mobility in Parkinson disease. Phys. Ther., 2016 (Epub ahead of print).
134. [134] King, L.A., Peterson, D.S., Mancini, M., Carlson-Kuhta, P., Fling, B.W., Smulders, K., Nutt, J.G., Dale, M., Carter, J., Winters-Stone, K.M., Horak, F.B., Do cognitive measures and brain circuitry predict outcomes of exercise in Parkinson Disease: a randomized clinical trial. BMC Neurol., 15, 2015, 218.
135. [135] Mancini, M., Fling, B.W., Gendreau, A., Lapidus, J., Horak, F.B., Chung, K., Nutt, J.G., Effect of augmenting cholinergic function on gait and balance. BMC Neurol., 15(1), 2015, 264.
136. [136] Litvinenko, I.V., Odinak, M.M., Mogil'naya, V.I., Emelin, A.Y., Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial). Neurosci. Behav. Physiol. 38:9 (2008), 937–945.